Nystin

Quick links to important sections

Nystin

Treatment option: Infection, Oral Cavity

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nystin

Property Description
Active Ingredient Nystatin
Pharmacological Class Polyene Antifungal
Common Use Management of local Candidiasis
Origin Natural (Derived from Streptomyces noursei)
Forms Tablets, Oral Suspension, Cream, Ointment

Nystin is the commercial name for a medication whose sole active substance is Nystatin, officially recognized as the INN (International Nonproprietary Name). Nystatin is classified as a polyene antifungal agent and a macrolide antibiotic, a dual designation reflecting its origin and therapeutic action. This agent is of natural origin, biosynthesized from the bacterium Streptomyces noursei, distinguishing its source from purely synthetic antimycotic alternatives. Nystatin is clinically recognized for its role in treating mucosal candidiasis.

Nystin is available in various dosage forms, including tablets, oral suspension (prepared in an aqueous base), and topical cream or ointment, facilitating targeted administration via oral or mucocutaneous routes. The primary therapeutic purpose of Nystin is the effective management of infections caused by susceptible fungi and yeast, particularly Candidiasis. Due to its characteristic property of being minimally absorbed into the bloodstream from the gastrointestinal tract or skin, Nystin’s use is predominantly localized, providing a targeted defense against surface mycotic infections.

Nystatin works by disrupting the structural integrity of the fungal cell membrane; it selectively binds to ergosterol, a crucial lipid found only in the fungal cell. This binding action compromises the membrane, ensuring the specific neutralization or elimination of the fungal pathogen. This distinct mechanism confers low systemic toxicity when the medicine is used for local treatment.

Regulatory References

  1. FDA Nystatin Classification
  2. WHO Model List of Essential Medicines
  3. NIH Nystatin Review

What side effects are possible with Nystin?

Possible side effects and safety information

The safety profile of Nystin (nystatin) is characterized by adverse reactions that are primarily localized to the site of administration, which is consistent with the drug’s minimal systemic absorption. Side effects are officially classified according to the organ system affected.

Adverse Reaction Groupings

System-Organ Class Common Adverse Reactions
Gastrointestinal Disorders Nausea, vomiting, diarrhea, gastrointestinal upset, abdominal discomfort.
Skin and Mucous Tissue Oral irritation, sensitization, rash, and urticaria.

Serious and Less Frequent Reactions

Certain reactions are documented in official regulatory sources, though they occur less frequently. Severe immune responses, classified as hypersensitivity reactions (including anaphylactic shock), have been reported. Rare but serious dermatologic reactions, such as Stevens-Johnson syndrome, have also been noted in regulatory documents, with a classification of very rarely reported.

Safety Restrictions and Special Populations

Nystin is contraindicated in patients with a known history of hypersensitivity to any of its components. Official labeling explicitly states that the medication is not to be used for the treatment of systemic mycoses (internal fungal infections).

Special safety considerations apply to certain patient groups. In individuals with renal insufficiency receiving oral nystatin, regulatory information notes that significant plasma concentrations may occasionally occur. For pregnancy, Nystin is classified as Category C for Teratogenic Effects, and administration is advised only if clearly needed.

Overdose and Emergency Response

The official regulatory profile for Nystin (nystatin) overdose is primarily defined by the drug's limited absorption across the gastrointestinal tract. Consequently, systemic toxic effects are not anticipated following acute overdose of the oral or topical formulations.


Documented Overdose Manifestations

Property Official Regulatory Statement
Documented presentations Primarily gastrointestinal distress, including nausea, vomiting, and diarrhea are the noted clinical signs associated with very high oral dosage.
Severe outcomes No serious toxic effects have been documented in regulatory records following overdose, reflecting a low risk of systemic toxicity.

Emergency Action and Management

In the event of a suspected overdose, immediate medical attention must be sought. Regulatory agencies mandate that individuals contact a regional poison control centre or call emergency services immediately if the affected person collapses or exhibits difficulty breathing.

The required medical management is generally symptomatic therapy and general supportive measures, as no specific antidote is known for Nystatin overdose. A specific regulatory consideration notes that in patients with renal insufficiency (impaired kidney function), significant plasma concentrations may occasionally occur during oral therapy.

Therapeutic Uses of Nystin

Nystin (nystatin) is a medication that assists in managing infections caused by Candida species, which are a type of fungus. Its therapeutic application focuses on localized fungal conditions of the body.

Quick Facts

  • Targeted Conditions: Oral candidiasis (thrush), cutaneous (skin) candidiasis, and non-esophageal gastrointestinal candidiasis.
  • Therapeutic Action: Contributes to the elimination of susceptible fungal organisms at the infection site.

Nystin is indicated for the treatment of candidiasis present in the oral cavity. The oral suspension formulation is commonly utilized for this purpose. Furthermore, nystatin formulations are employed for the management of fungal infections affecting the skin, including cutaneous candidiasis, as well as those localized within the gastrointestinal tract, specifically non-esophageal mucous membrane candidiasis. Treatment with nystatin may also be prescribed to individuals considered to be at high risk for developing oral or intestinal candidiasis to help prevent the onset of these infections.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Nystin — official regulatory information

This section outlines the official population eligibility and non-eligibility rules for Nystin (Nystatin) based exclusively on governmental regulatory documentation.


Eligibility Scope

Populations for whom use is contraindicated:

  • Patients with a known history of hypersensitivity (allergy) to Nystatin or any of the product's excipients.

Populations for whom use is not recommended:

  • Patients requiring systemic treatment for fungal infections, as Nystin is minimally absorbed and is ineffective against systemic disease.
  • Patients with rare hereditary problems of fructose intolerance, glucose–galactose malabsorption, or sucrose–isomaltase insufficiency (applies to sucrose-containing formulations).

Age-related eligibility rules:

  • Adults and Older Adults: Use is established with no special dose adjustments mandated solely based on age.
  • Infants and Children: Use is established for localized candidiasis, with liquid formulations preferred for younger patients.

Pregnancy and lactation eligibility status:

  • Pregnancy: Use is generally permitted only if clearly needed, primarily due to the drug’s minimal systemic absorption.
  • Lactation: Caution is advised, as it is not known whether Nystatin is excreted in human milk.

Condition-specific eligibility rules:

  • Renal and Hepatic Impairment: No specific dose adjustments are generally recommended, consistent with the drug's minimal systemic absorption.

What should I know about interactions with other medicines?

The official regulatory profile for Nystin (Nystatin) is primarily defined by the drug’s pharmacological property of minimal systemic absorption. This characteristic is consistently documented across government prescribing information and dictates the nature and scope of its interaction profile.


Interaction Structure

Interaction Entity Regulatory Status
Systemic Drug-Drug Interactions None documented as clinically relevant.
Formal Contraindicated Combinations None documented.
Metabolic (CYP) Interactions None documented.
Exposure-Modifying Substances None documented.

Official Interaction Summary

Regulatory documents confirm that Nystatin is negligibly absorbed from the gastrointestinal tract and mucous membranes, meaning it does not achieve the necessary plasma concentrations to participate in systemic metabolic processes, such as those involving Cytochrome P450 enzymes. This systemic pharmacokinetic profile is the basis for the absence of documented clinically significant drug-drug interactions with co-administered medicines.

Consequently, there are no official restrictions, mandatory timing requirements, or formal contraindications listed in regulatory labels that are based on a systemic interaction risk. The official interaction map is constrained by the drug's localized action, which defines the product's profile concerning co-administration.

Mechanism of Action

Nystin (Nystatin) employs a highly specific mechanism that physically disrupts the fungal cell structure. The initial step involves the molecule binding with strong affinity to ergosterol, a sterol essential for the structural integrity of the fungal cell membrane, thereby establishing selective molecular targeting. .

Upon binding, Nystatin aggregates to form transmembrane pores or channels, which immediately compromises the membrane's barrier function. This physical damage leads to the rapid, uncontrolled leakage of vital intracellular electrolytes, such as potassium ions (K^+). The resulting collapse of the cell's electrochemical and osmotic stability culminates in fungal cell lysis (breakdown and death), which is a localized fungicidal consequence.

The mechanism is intrinsically limited to a peripheral, local action at the application site. Due to its physical constraints and lack of systemic activity, the action cannot extend into systemic or deep-seated tissues, establishing the functional limits of the biological action.

Dosage and Administration Information

How to Use Nystin

The use of Nystin (nystatin) is strictly localized, with administration defined by the site of the fungal infection. Official routes include oral (using tablets or suspension for the gastrointestinal tract), topical for the skin, and intravaginal for specific mucosal sites.


Administration Regimens and Frequency

The oral suspension is typically dosed at 400,000 to 600,000 units per dose and taken four times daily. Oral tablets for non-esophageal intestinal conditions are usually administered at 500,000 to 1,000,000 units three times daily. For cutaneous infections, a sufficient quantity of cream, ointment, or powder is applied two to three times daily. Specific lower dosages are prescribed for infants, such as 100,000 units four times daily.


Administration Technique and Course Duration

For oral candidiasis, a key administration principle is to shake the suspension well before use and retain the liquid in the mouth for several minutes before swallowing to ensure prolonged contact with the infection site. Treatment duration is label-specified, often lasting 7 to 14 days, with an official instruction that administration must be continued for at least 48 hours after all clinical symptoms have disappeared to prevent recurrence. Nystin products labeled for topical use are strictly for external application.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Clinical Trials

Research has investigated the drug's potential effects and how it may influence fungal colonization in various patient populations.

  • The drug was studied to explore its mechanism of action.
  • In clinical trials, a change in symptom severity compared to baseline was measured.
  • The primary study endpoint was typically defined as the change in clinical and mycological cure rates after a defined treatment period.

Comparative Outcomes

Studies have examined the use of Nystin compared to other antifungal agents or placebo in specific patient groups.

  • A meta-analysis of clinical trials examined outcomes for Nystin in various forms compared to other treatments for oral candidiasis.
  • This research focused on objective measures, such as the reduction in Candida colony-forming units (CFU/mL) and overall clinical remission.
  • In one trial, Nystin was studied to explore outcomes in preventing systemic fungal infection in very low birth weight preterm infants compared to sterile water.

Safety and Tolerability Profile Research

Clinical trials examined the overall safety and tolerability profile across the patient population, focusing primarily on topical and oral administration.

  • Studies focusing on specific populations, such as people with mild-to-moderate candidiasis, were conducted to examine outcomes.
  • Another trial explored outcomes related to pain and mobility in participants receiving the drug.
  • Further long-term studies are ongoing to evaluate outcomes beyond the initial trial period.

Key Studies & References

  1. Comparison of Antifungal Efficacy of Zataria Multiflora and Nystatin for Treatment of Denture Stomatitis: A Randomized Clinical Trial
  2. Nystatin Oral Suspension USP - NIH DailyMed (FDA Labeling)

Frequently Asked Questions (FAQ)

Common questions about Nystin (FAQ)


Q: How quickly does Nystin start to work after taking it?

Official information indicates that for the liquid suspension used orally, patients may start to notice symptomatic relief after about two days of treatment. For topical creams or ointments applied to the skin, symptomatic improvement may become apparent within 24 to 72 hours.


Q: What is the usual time it takes to complete the treatment with Nystin?

According to regulatory prescribing information, the typical duration of treatment for oral infections is described as 7 to 14 days. For fungal infections of the skin, a shorter course, often 7 to 10 days, is typically used.


Q: What should I do if I miss a dose of Nystin?

Patient guidance suggests taking the dose as soon as it is remembered. However, if it is less than three hours before the next scheduled dose, official guidance suggests that the missed dose be skipped. Official documents emphasize that a double dose should never be taken to make up for a missed one.


Q: Is it okay to stop using Nystin if my symptoms disappear early?

Official instructions indicate administration should be continued and not interrupted before the full prescribed course is finished. It is often directed that treatment should continue for at least 48 hours after all visible symptoms have disappeared to manage the potential for recurrence.


Q: Can Nystin be used for skin fungal infections?

Yes, Nystin is officially formulated as a cream, ointment, or powder to treat fungal or yeast infections specifically of the skin. The drug's localized action is consistent with its use for these topical applications.


Q: What are the most common side effects reported for Nystin?

Regulatory documents describe the most frequently reported adverse reactions as involving the gastrointestinal system. These include symptoms such as diarrhea, nausea, vomiting, and general stomach discomfort or upset.


Q: Does Nystin cause upset stomach or digestive issues?

Yes, official documents list adverse reactions under Gastrointestinal Disorders. These are described as including gastrointestinal distress or upset, nausea, vomiting, and diarrhea.


Q: Is there a risk of developing a serious allergic reaction to Nystin?

Regulatory information notes that hypersensitivity reactions, including anaphylaxis, have been reported. Rare and severe dermatological reactions, such as Stevens-Johnson syndrome, have also been noted in official reports.


Q: Are there any known food or drink interactions with Nystin?

Because Nystatin is negligibly absorbed into the bloodstream, systemic interactions with food or drink are not anticipated, which is consistent with its minimal absorption. However, patient guidance for the oral suspension often suggests not mixing the liquid formulation with food or water.


Q: Why is Nystin sometimes used in combination with other drugs?

Nystatin is sometimes formulated in topical combination products, most commonly with corticosteroids. This use is generally aimed at managing associated symptoms, such as inflammation, alongside the treatment of the fungal infection itself.


Q: Can Nystin change the color or texture of body waste?

While regulatory documents list gastrointestinal side effects such as diarrhea and stomach upset, there is no explicit mention that Nystin changes the color or texture of body waste.


Q: Does Nystin cause fatigue or tiredness?

Fatigue or tiredness is not listed among the documented systemic adverse reactions in official regulatory labels for single-ingredient Nystatin. The safety profile, as described in regulatory documents, highlights localized and gastrointestinal effects.


Q: What are the possible signs that Nystin is not working?

The possible signs are described as a lack of therapeutic response, meaning the symptoms persist or worsen. If this occurs, regulatory documents indicate that repeating appropriate microbiological studies is advised to confirm the diagnosis.


Q: What is the typical dosage strength of Nystin prescribed?

Common dosage strengths for the oral suspension in adults are typically 400,000 to 600,000 units four times a day. Tablets for intestinal conditions are commonly prescribed at 500,000 to 1,000,000 units three times a day.


Q: What if I experience a rare or unexpected side effect with Nystin?

Regulatory labels provide instructions for patients and healthcare providers to report suspected adverse reactions. These reports are submitted directly to the drug manufacturer or the equivalent local health authority, such as the FDA or EMA.


Q: Is Nystin known to interact with herbal supplements?

Official interaction documents confirm the absence of clinically significant drug-drug interactions, which is attributed to Nystatin being negligibly absorbed by the body. This minimal systemic activity means that interactions with most herbal supplements are not expected.


Q: Is Nystin sometimes used as a preventative measure?

Official guidance indicates that Nystatin has been studied for antifungal prophylaxis in certain eligible, high-risk patients. This is sometimes seen in specific high-risk groups, such as very low birth weight preterm neonates.


Q: Is Nystin primarily eliminated through the kidneys or the liver?

Pharmacokinetic data indicates that Nystatin is insignificantly absorbed from the gastrointestinal tract or skin. Because of this, most of the orally administered drug is passed out of the body unchanged in the stool, rather than being processed by the liver or kidneys.


Q: Does Nystin contain lactose or gluten?

Regulatory documents that list inactive ingredients, particularly for the oral suspension, commonly include substances like sucrose. However, official lists for these specific formulations do not typically include lactose or gluten as components.


Q: What are the general expectations for relief when using Nystin?

General expectations for relief are described in patient guidance as typically starting around two days after beginning the liquid suspension treatment. However, it is important to complete the full course as prescribed to manage the potential for recurrence.

How should Nystin be stored and disposed of?

How to Store and Dispose of Nystatin (Nystin)

Storage and disposal requirements for Nystatin are defined by regulatory authorities to ensure product stability and safety. Most formulations must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F).

Key Storage Rules

  • Temperature: Avoid freezing the oral suspension and ointment. Tablets must be stored below 25 C.
  • Protection: The oral suspension must be protected from light and kept in a tightly closed container.
  • Child Safety: All forms must be kept out of the reach of children, as mandated by regulatory labeling.

Disposal

Unused or expired Nystatin must be disposed of in accordance with local requirements and should not be discarded into wastewater or common household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nystin found in:

A-Z Index: